Best Mode-Biosimilars-Biotech/Pharma Business-Biotech/Pharma News-Board of Patent Appeals-Interferences-Claim Construction-Double-Patenting-Enablement-Federal Circuit-Food and Drug Administration-Hatch-Waxman-Inequitable Conduct-Infringement-Contributory-Induced-Infringement - Literal-DOE-Injunction
